| Literature DB >> 33623843 |
Ling-Feng Zhou1, Jun Wu1, Shuai Li2, Qi Li3, Li-Ping Jin2, Cai-Ping Yin1, Ying-Lao Zhang1.
Abstract
Twenty-one strains of termite-associated actinomycetes were tested for their activities against three bacteria. The results showed that nine strains showed bacteriostatic activities against at least one tested bacterium, and the actinomycete YH01, which was isolated from the body surface of the queen of Odontotermes formosanus, had potent antibacterial activity. The YH01 was further identified as Streptomyces davaonensis. Two metabolites roseoflavin (1) and 8-methylamino-8-demethyl-d-riboflavin (2) were isolated and purified from S. davaonensis YH01. Their structures were determined by NMR, MS, and the related literature. The metabolite 1 showed strong inhibition activities against Bacillus subtilis (MIC = 1.56 μg/mL) and Staphylococcus aureus (MIC = 3.125 μg/mL), which were comparable to referenced gentamycin sulfate, with MIC values of 1.56 and 1.56 μg/mL, respectively. Furthermore, the anti-MRSA potential of compound 1 was determined against nine kinds of MRSA strains, with inhibition zones in the ranges of 12.7-19.7 mm under a concentration of 15 μg/6 mm discs and 18.3-22.7 mm under a concentration of 30 μg/6 mm discs. However, metabolite 1 had no inhibitory effect on Gram-negative bacteria. These results suggested that roseoflavin produced by YH01 holds promise for use against Gram-positive bacteria, especially to MRSA.Entities:
Year: 2021 PMID: 33623843 PMCID: PMC7893633 DOI: 10.1021/acsomega.0c05580
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Inhibition Zone Diameters of Inhibiting Effects of Actinomycetes on Three Tested Bacteria (mm)
| strain | strain | ||||||
|---|---|---|---|---|---|---|---|
| T45 | NI | NI | NI | T60 | NI | NI | NI |
| T14 | NI | NI | NI | T16 | 14.0 ± 0.1 | 12.0 ± 0.0 | NI |
| T44 | NI | 14.5 | 14.5 ± 0.5 | T55 | 17.5 ± 0.5 | 17.0 ± 1.0 | NI |
| T21 | NI | NI | NI | T9 | 13.0 ± 0.7 | 11.5 ± 0.7 | 14.3 ± 2.84 |
| T17 | 18.3 ± 1.0 | 16.0 ± 0.5 | NI | T1 | 17.1 ± 0.2 | 9.5 ± 0.0 | 12.0 ± 1.2 |
| T25 | NI | NI | NI | T38 | NI | NI | NI |
| T10 | NI | NI | NI | T54 | 19.8 ± 1.8 | 20.6 ± 0.9 | NI |
| T61 | 11.3 ± 1.1 | 11.9 ± 0.1 | 11.6 ± 0.4 | T57 | NI | NI | NI |
| T19 | NI | NI | NI | T58 | NI | NI | NI |
| T40 | NI | NI | NI | YH01 | NI | 15 ± 0.5 | 30 ± 1.2 |
| T8 | NI | NI | NI | PC | 23.0 ± 0.5 | 23.2 ± 0.2 | 25.5 |
NI = not inhibited.
PC: gentamicin sulfate was used as a positive control.
Figure 1Phylogenetic tree obtained by neighbor joining analysis of 16S rRNA gene sequences showing the relationship between YH01 and related species belonging to genus Streptomyces obtained from the Ezbiocloud database. The numbers on branch nodes are bootstrap values (expressed as a percentage of 1000 replications).
Figure 2Chemical structures of secondary metabolites 1 and 2.
MICs (μg/mL) of Compound 1 against the Tested Bacteria
| tested bacteria | gentamicin sulfate | |
|---|---|---|
| 1.56 | 1.56 | |
| 3.125 | 1.56 | |
| >25 | 12.5 | |
| >25 | 3.125 |
Zones of Inhibition (mm) of Compound 1 against a Variety of MRSA
| MRSA strain | 30 μg/dics | 15 μg/dics |
|---|---|---|
| MRSA01 | 18.3 | 15.3 |
| MRSA02 | 21.0 | 19.0 |
| MRSA03 | 18.7 | 17.3 |
| MRSA04 | 20.3 | 12.7 |
| MRSA05 | 22.7 | 19.7 |
| MRSA06 | 20.7 | 18.3 |
| MRSA07 | 21.7 | 18.7 |
| MRSA08 | 21.0 | 19.3 |
| MRSA09 | 18.3 | 16.0 |
Figure 3Antibacterial activity of compound 1 (30 μg/6 mm dics) against MRSA05.